Conversely, treatment with anti-HLA-G antibody did not alter the rate of AR in primary CLL cells, while ZCL278 treatment reduced the AR in three out of five patients (Figure 6B). Here, HLA-G is linked to B-cell chronic lymphocytic leukemia.